CanSino's inhalable Covid-19 vaccine gets clinical trial approval in Malaysia, says Solution Group

The inhalable version of CanSino’s Recombinant Covid-19 Vaccine (Adenovirus Type 5 Vector) has received clinical trial approval in Malaysia, says Solution Group Bhd (SGB).

Related Keywords

China ,Kuala Lumpur ,Malaysia ,Lampang ,Malaysia General ,Biontech Covid ,Mohd Nazlee ,Mohd Nazlee Kamal ,Pfizer ,Solution Group Bhd ,China National Medical Products Administration ,South China Morning Post ,Ethics Committee ,Ministry Of Health ,Adenovirus Type ,Medical Research ,Convidecia Air ,Datuk Dr Mohd Nazlee ,Ampang Hospital ,Selayang Hospital ,National Medical Products Administration ,